Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-β1/IL-2/COX-2/endothelin ETB receptor cascade

Toxicology and Applied Pharmacology

Volumn 275, Issue 2, 2014, Pages 88-95

  El Gowelli, Hanan M ^a   Helmy, Maged W ^b   Ali, Rabab M ^b   El Mas, Mahmoud M ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b Pharos University of Alexandria   (Egypt)

Author keywords

Celecoxib; Cyclooxygenase 2; Cyclosporine; Endothelin ETB receptor; Kidney

Indexed keywords

CELECOXIB; CYCLOOXYGENASE-2; CYCLOSPORINE; ENDOTHELIN ET(B) RECEPTOR; KIDNEY;

ANIMALS; CREATININE; CYCLOOXYGENASE 2; CYCLOSPORINE; FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; KIDNEY; KIDNEY DISEASES; MALE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84894029089     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.01.008     Document Type: Article

References (61)

1. Abassi Z., Brodsky S., Gealekman O., Rubinstein I., Hoffman A., Winaver J. Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure. Am. J. Physiol. Renal Physiol. 2001, 280:F43-F53.
2. Ash Z., Gaujoux-Viala C., Gossec L., Hensor E.M., FitzGerald O., Winthrop K., van der Heijde D., Emery P., Smolen J.S., Marzo-Ortega H. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann. Rheum. Dis. 2012, 71:319-326.
3. Bijman M.N., Hermelink C.A., van Berkel M.P., Laan A.C., Janmaat M.L., Peters G.J., Boven E. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem. Pharmacol. 2008, 75:427-437.
4. Bonner J.C., Rice A.B., Ingram J.L., Moomaw C.R., Nyska A., Bradbury A., Sessoms A.R., Chulada P.C., Morgan D.L., Zeldin D.C., Langenbach R. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am. J. Pathol. 2002, 161:459-470.
5. Boomer J.S., Green J.M. An enigmatic tail of CD28 signaling. Cold Spring Harb. Perspect. Biol. 2010, 2(8):a002436.
6. Cauduro R.L., Costa C., Lhulier F., Garcia R.G., Cabral R.D., Gonçalves L.F., Manfro R.C. Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin. Transplant. 2005, 19:470-474.
7. Cavalcante E.G., Aikawa N.E., Lozano R.G., Lotito A.P., Jesus A.A., Silva C.A. Chronic polyarthritis as the first manifestation of juvenile systemic lupus erythematosus patients. Lupus 2011, 20:960-964.
8. Cervello M., Bachvarov D., Cusimano A., Sardina F., Azzolina A., Lampiasi N., Giannitrapani L., McCubrey J.A., Montalto G. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS 2011, 15:383-392.
9. Chatterjee P.K., Cuzzocrea S., Brown P.A., Zacharowski K., Stewart K.N., Mota-Filipe H., Thiemermann C. Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int. 2000, 58:658-673.
10. Chen G.F., Sun Z. Effects of chronic cold exposure on the endothelin system. Appl. Physiol. 2006, 100:1719-1726.
11. Davenport A.P., Maguire J.J. Pharmacology of renal endothelin receptors. Contrib. Nephrol. 2011, 172:1-17.
12. Dinchuk J.E., Car B.D., Focht R.J., Johnston J.J., Jaffee B.D., Covington M.B., Contel N.R., Eng V.M., Collins R.J., Czerniak P.M., et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995, 378:406-409.
13. Drury R.A.B., Wallington E.A. Carleton's Histological Techniques 1980, Oxford University Press, New York. 5th ed.
14. Duque J., Fresno M., Iñiguez M.A. Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2. J. Biol. Chem. 2005, 280:8686-8693.
15. El-Gowelli H.M., Abd-Elrahman K.S., Saad E.I., El-gowilly S.M., Abdel-Galil A.A., El-Mas M.M. PPARγ dependence of cyclosporine-isoprenaline renovascular interaction: roles of nitric oxide synthase and heme oxygenase. J. Cardiovasc. Pharmacol. 2011, 58:173-180.
16. El-gowilly S.M., Ghazal A.M., Gohar E.Y., El-Mas M.M. Exacerbation by nicotine of the cyclosporine A-induced impairment of β-adrenoceptor-mediated renal vasodilation in rats. Clin. Exp. Pharmacol. Physiol. 2008, 35:1164-1171.
17. El-Mas M.M., Afify E.A., Omar A.G., Mohy El-Din M.M., Sharabi F.M. Testosterone depletion contributes to cyclosporine-induced chronic impairment of acetylcholine renovascular relaxations. Eur. J. Pharmacol. 2003, 468:217-224.
18. El-Mas M.M., Afify E.A., Omar A.G., Sharabi F.M. Cyclosporine adversely affects baroreflexes via inhibition of testosterone modulation of cardiac vagal control. J. Pharmacol. Exp. Ther. 2002, 301:346-354.
19. El-Mas M.M., Afify E.A., Omar A.G., Sharabi F.M. Cyclosporine attenuates the autonomic modulation of reflex chronotropic responses in conscious rats. Can. J. Physiol. Pharmacol. 2002, 80:766-776.
20. El-Mas M.M., El-Gowelli H.M., Abd-Elrahman K.S., Saad E.I., Abdel-Galil A.G., Abdel-Rahman A.A. Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function. Biochem. Pharmacol. 2011, 81:526-533.
21. El-Mas M.M., Mohy El-Din M.M., El-gowilly S.M., Sharabi F.M. Regional and endothelial differences in the cyclosporine attenuation of adenosine receptor-mediated vasorelaxations. J. Cardiovasc. Pharmacol. 2004, 43:562-573.
22. El-Mas M.M., Mohy El-Din M.M., El-gowilly S.M., Sharabi F.M. Relative roles of endothelial relaxing factors in cyclosporine-induced impairment of cholinergic and β-adrenergic renal vasodilations. Eur. J. Pharmacol. 2004, 487:149-158.
23. El-Mas M.M., Zhang J., Abdel-Rahman A.A. Upregulation of vascular inducible nitric oxide synthase mediates the hypotensive effect of ethanol in conscious female rats. J. Appl. Physiol. 2006, 100:1011-1018.
24. Fu L.W., Guo Z.L., Longhurst J.C. Endogenous endothelin stimulates cardiac sympathetic afferents during ischemia. J. Physiol. 2010, 588:2473-2486.
25. Fujihara C.K., Antunes G.R., Mattar A.L., Andreoli N., Malheiros D.M., Noronha I.L., Zatz R. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney Int. 2003, 64:2172-2181.
26. Ghosh P., Buchholz M.A., Yano S., Taub D., Longo D.L. Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway. Blood 2002, 99:4517-4524.
27. Han S.H., Yea S.S., Jeon Y.J., Yang K.H., Kaminski N.E. Transforming growth factor-beta 1 (TGF-beta1) promotes IL-2 mRNA expression through the up-regulation of NF-kappaB, AP-1 and NF-AT in EL4 cells. J. Pharmacol. Exp. Ther. 1998, 287:1105-1112.
28. Hao C.M., Breyer M.D. Physiological regulation of prostaglandins in the kidney. Annu. Rev. Physiol. 2008, 70:357-377.
29. Hardy G., Stanke-Labesque F., Deveaux G., Devillier P., Sessa C., Bessard G. Cyclosporine A and cremophor EL induce contractions of human saphenous vein: involvement of thromboxane A2 receptor-dependent pathway. J. Cardiovasc. Pharmacol. 2000, 36:693-698.
30. Harris R.C., Breyer M.D. Physiological regulation of cyclooxygenase-2 in the kidney. Am. J. Physiol. Renal Physiol. 2001, 281:F1-F11.
31. Hazzan M., Hertig A., Buob D., Copin M.C., Noël C., Rondeau E., Dubois-Xu Y.C. Epithelial-to-mesenchymal transition predicts cyclosporine nephrotoxicity in renal transplant recipients. J. Am. Soc. Nephrol. 2011, 22:1375-1381.
32. Helmy M.M., El-Gowelli H.M. Montelukast abrogates rhabdomyolysis-induced acute renal failure via rectifying detrimental changes in antioxidant profile and systemic cytokines and apoptotic factors production. Eur. J. Pharmacol. 2012, 683:294-300.
33. Herlitz H., Lindelöw B. Renal failure following cardiac transplantation. Nephrol. Dial. Transplant. 2000, 15:311-314.
34. Hétu P.O., Riendeau D. Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. Biochem. J. 2005, 391(Pt 3):561-566.
35. Iñiguez M.A., Punzón C., Cacheiro-Llaguno C., Díaz-Muñoz M.D., Duque J., Cuberes R., Alvarez I., Andrés E.M., Buxens J., Buschmann H., Vela J.M., Fresno M. Cyclooxygenase-independent inhibitory effects on T cell activation of novel 4,5-dihydro-3 trifluoromethylpyrazole cyclooxygenase-2 inhibitors. Int. Immunopharmacol. 2010, 10:1295-1304.
36. Kaczmarek E., Górna A., Majewski P. Techniques of image analysis for quantitative immunohistochemistry. Ann. Acad. Med. Bialostocensis 2004, 49(Suppl. 1):155-158.
37. Khan E., Batuman V., Lertora J.J. Emergence of biomarkers in nephropharmacology. Biomark. Med 2010, 4:805-814.
38. Klintmalm G.B.G., Iwatsuki S., Starzl T.E. Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet 1981, 1:470-471.
39. Kovarik J.M., Burtin P. Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin. Emerg. Drugs 2003, 8:47-62.
40. Lin C.C., Hsieh H.L., Shih R.H., Chi P.L., Cheng S.E., Yang C.M. Up-regulation of COX-2/PGE2 by endothelin-1 via MAPK-dependent NF-κB pathway in mouse brain microvascular endothelial cells. Cell Commun. Signal. 2013, 11:8. 10.1186/1478-811X-11-8.
41. Liu F., Mih J.D., Shea B.S., Kho A.T., Sharif A.S., Tager A.M., Tschumperlin D.J. Feedback amplification of fibrosis through matrix stiffening and COX-2suppression. J. Cell Biol. 2010, 190:693-706.
42. Matsumura T., Suzuki T., Aizawa K., Sawaki D., Munemasa Y., Ishida J., Nagai R. Regulation of transforming growth factor-beta-dependent cyclooxygenase-2 expression in fibroblasts. J. Biol. Chem. 2009, 284:35861-35871.
43. Miller L.W. Cardiovascular toxicities of immunosuppressive agents. Am. J. Transplant. 2002, 2:807-818.
44. Niederberger E. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kB. Pharmazentrum FASEB J 2011, 15:1622-1624.
45. Nishiyama A., Kobori H., Fukui T., Zhang G.X., Yao L., Rahman M., Hitomi H., Kiyomoto H., Shokoji T., Kimura S., Kohno M., Abe Y. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 2003, 42:754-760.
46. Ohkita M., Takaoka M., Matsumura Y. Drug discovery for overcoming chronic kidney disease (CKD): the endothelin ET B receptor/nitric oxide system functions as a protective factor in CKD. J. Pharmacol. Sci. 2009, 109:7-13.
47. Olyaei A.J., de Mattos A.M., Bennett W.M. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Saf. 1999, 21:471-488.
48. Opitz C.F., Ewert R. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. Eur. J. Clin. Invest. 2006, 36(Suppl. 3):1-9.
49. Papachristou E., Papadimitropoulos A., Kotsantis P., Goumenos D.S., Katsoris P.G., Vlachojannis J.G. Cyclosporine induces endothelin-1 mRNA synthesis and nitric oxide production in human proximal tubular epithelial cell cultures. Ren. Fail. 2009, 31:372-376.
50. Pasic M.D., Colantonio D.A., Chan M.K., Venner A.A., Brinc D., Adeli K. Influence of fasting and sample collection time on 38 biochemical markers in healthy children: a CALIPER substudy. Clin. Biochem. 2012, 45:1125-1130.
51. Paul L.C., de Fijter J.H. Cyclosporine-induced renal dysfunction. Transplant. Proc. 2004, 36:224S-228S.
52. Pérez-Rojas J.M., Derive S., Blanco J.A., Cruz C., Martínez de la Maza L., Gamba G., Bobadilla N.A. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am. J. Physiol. Renal Physiol. 2005, 289:F1020-F1030.
53. Quesniaux V.F. Immunosuppressants: tools to investigate the physiological role of cytokines. Bioessays 1993, 15:731-739.
54. Roos-van Groningen M.C., Scholten E.M., Lelieveld P.M., Rowshani A.T., Baelde H.J., Bajema I.M., Florquin S., Bemelman F.J., de Heer E., de Fijter J.W., Bruijn J.A., Eikmans M. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J. Am. Soc. Nephrol. 2006, 17:881-888.
55. Singh M., Chaudhry P., Parent S., Asselin E. Ubiquitin-proteasomal degradation of COX-2 in TGF-β stimulated human endometrial cells is mediated through endoplasmic reticulum mannosidase I. Endocrinology 2012, 153:426-437.
56. Stacchiotti A., Lavazza A., Rezzani R., Bianchi R. Cyclosporine A-induced kidney alterations are limited by melatonin in rats: an electron microscope study. Ultrastruct. Pathol. 2002, 26:81-87.
57. Suddek G.M., El-Kenawi A.E., Abdel-Aziz A., El-Kashef H.A. Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity. Chemotherapy 2011, 57:321-326.
58. Vancheri C., Mastruzzo C., Sortino M.A., Crimi N. The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol. 2004, 25:40-46.
59. Warner L., Yin M., Glaser K.J., Woollard J.A., Carrascal C.A., Korsmo M.J., Crane J.A., Ehman R.L., Lerman L.O. Noninvasive in vivo assessment of renal tissue elasticity during graded renal ischemia using MR elastography. Invest. Radiol. 2011, 46:509-514.
60. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int. 2006, 70:1914-1919.
61. Zhan Y., Wang Y., Wei L., Chen H. Effects of vitamin E on the proliferation and collagen synthesis of rat hepatic stellate cells treated with IL-2 or TNF-alpha. Chin. Med. J. (Engl.) 2003, 116:472-474.